<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647721</url>
  </required_header>
  <id_info>
    <org_study_id>M900311009</org_study_id>
    <nct_id>NCT04647721</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness and Safety of Radiesse for the Correction of Moderate to Severe Nasolabial Folds</brief_title>
  <official_title>Evaluation of the Effectiveness and Safety of Radiesse for the Correction of Moderate to Severe Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effectiveness: The purpose of this study is to demonstrate the non-inferiority of Radiesse&#xD;
      (CaHA) to Restylane (HA) following subdermal implantation for the correction of moderate to&#xD;
      severe facial wrinkles and folds, such as NLFs.&#xD;
&#xD;
      Safety: To evaluate the incidence and type of adverse events and serious adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Split-face</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Week 24 on the Wrinkle Severity Rating Scale (WSRS)</measure>
    <time_frame>Week 24</time_frame>
    <description>The Wrinkle Severity Rating Scale (WSRS) is a 5-point scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with improvement on the Investigator Global Aesthetic Improvement Scale (iGAIS) for each NLF at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with any improvement on the Subject Global Aesthetic Improvement Scale (sGAIS) for each NLF at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events related to Radiesse</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Correction of Moderate to Severe Nasolabial Folds (NLFs)</condition>
  <arm_group>
    <arm_group_label>Left side Radiesse® / Right side Restylane®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Left side Restylane® / Right side Radiesse®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiesse injectable implant (dermal filler)</intervention_name>
    <description>Subdermal injection.</description>
    <arm_group_label>Left side Radiesse® / Right side Restylane®</arm_group_label>
    <arm_group_label>Left side Restylane® / Right side Radiesse®</arm_group_label>
    <other_name>Calcium hydroxylapatite particles suspended in an aqueous based gel carrier.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane injectable implant (dermal filler)</intervention_name>
    <description>Subdermal injection.</description>
    <arm_group_label>Left side Radiesse® / Right side Restylane®</arm_group_label>
    <arm_group_label>Left side Restylane® / Right side Radiesse®</arm_group_label>
    <other_name>Hyaluronic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has symmetrical NLFs, with the same WSRS score of 3 or 4 (moderate or severe) for both&#xD;
             right and left NLFs, as determined on live assessment by the blinded evaluator.&#xD;
&#xD;
          -  Is ≥ 22 and ≤ 65 years of age.&#xD;
&#xD;
          -  Is willing to abstain from all other aesthetic treatments on any part of the face,&#xD;
             including but not limited to injectable fillers, implants, neurotoxin, skin peels,&#xD;
             laser treatments, surgical treatments, etc. for the trial's duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has an acute inflammatory process or active infection at the injection site.&#xD;
&#xD;
          -  Has received mid- and/or lower-facial region treatments with any dermal fillers.&#xD;
&#xD;
          -  Has received facial dermal therapies.&#xD;
&#xD;
          -  Had prior surgery in the mid- and/or lower-facial area, including the NLFs, or has a&#xD;
             permanent implant or graft in the mid- and/or lowerfacial area that could interfere&#xD;
             with effectiveness assessments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merz Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz North America, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University First Hospital, Merz Investigational Site #0860003</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital, Sun Yat-Sen University, Merz Investigational Site #0860023</name>
      <address>
        <city>Guangzhou</city>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Merz Investigational Site #0860030</name>
      <address>
        <city>Hangzhou</city>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital, Merz Investigational Site #0860005</name>
      <address>
        <city>Hangzhou</city>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RenMin Hospital of Wuhan University, Merz Investigational Site #0860014</name>
      <address>
        <city>Wuhan</city>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

